Klaus Peter Bøgesø, B. S, D.Sc, spent over 40 years at H. Lundbeck A/S, Copenhagen, Denmark. Starting in 1971 as medicinal chemist, he became Divisional Director of Medicinal Chemistry in 1986 and Vice President of Medicinal Chemistry Research in 1999. He has served on many boards and councils both in academia and in industry.
The research activities of Klaus P. Bøgesø have focused on drug design and development within psychiatric and neurological diseases such as schizophrenia, depression, anxiety, Alzheimer’s disease, Parkinson’s disease and epilepsy. Primary targets have been serotonin, dopamine and adrenergic receptors and transporters, muscarinic receptors and glutamate receptors.
Klaus P. Bøgesø is inventor of the selective serotonin reuptake inhibitor citalopram (cipramil, celexa) and its enantiomer escitalopram (cipralex, lexapro). He is the inventor of the 1-piperazino/1-amino-3-phenylindan drug class. In this class, he invented the potential antidepressants indatraline and Lu 17-133, the antipsychotics tefludazine , zicronapine and the 5-HT2A/2C antagonist irindalone. He and his team developed the atypical antipsychotic drug sertindole.
The differential action of stereoisomers of chiral drugs has been a focus area in many of the research projects Klaus P. Bøgesø has been involved in, as well as a main topic in several publications, including his doctoral thesis. Current research includes drug design at transporters for serotonin, noradrenaline and dopamine. A special focus area is drug design of compounds with selective affinity for the allosteric site of the human serotonin transporter.